Active ingredientPemigatinibCat. No. P-P036-001CAS 1513857-77-6Family · Pharmaceutical analytical standards
Pemigatinib
An inhibitor of fibroblast growth factor receptors (FGFR), approved in the United States in 2020 and in the European Union in 2021 for advanced cholangiocarcinoma with an FGFR2 fusion; since 2022 it has also been indicated for some myeloid/lymphoid neoplasms with FGFR1 rearrangement. This family brings together the active ingredient and other impurities.
Did you know?It was the first targeted treatment approved in the United States for cholangiocarcinoma, cancer of the bile ducts, together with a genetic test that identifies patients with the FGFR2 fusion.
Go to the active ingredient →Active ingredientPemigatinibCat. No. P-P036-001CAS 1513857-77-6
ImpurityPemigatinib Impurity 1Cat. No. P-P036-002
ImpurityPemigatinib Impurity 2Cat. No. P-P036-003
ImpurityPemigatinib N-OxideCat. No. P-P036-004No product matches your search.
Need a molecule you cannot find?
Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.